Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus: 阿卡波糖对中国2型糖尿病患者炎症因子及粪便双歧杆菌水平的作用
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: The effects of acarbose add‐on therapy on gut microbiota and inflammatory cytokines were investigated in C hinese patients with type 2 diabetes mellitus (DM). Methods: Ninety‐five DM patients were randomly allocated to two groups: 59 to Group A who received antidiabetic treatment that included acarbose 150 mg/day, and 36 to Group B who received similar treatment to Group A but without acarbose. Forty‐five healthy volunteers were selected as a control group. Serum concentrations of inflammatory cytokines were determined by ELISA, and the contents of 16S rDNA of gut bacteria were determined by real‐time quantitative polymerase chain reaction. General linear analysis for repeated measurements was used to analyze trend differences between the two diabetic groups. Results: After 4 weeks of antidiabetic treatment, the gut contents of B ifidobacterium longum and E nterococcus faecalis were significantly increased in both diabetes groups. The increase of B ifidobacterium longum (P = 0.004) and the decrease of lipopolysaccharides (LPS) (P < 0.001) and prothrombin activator inhibitor‐1 (P = 0.003) were more significant in Group A. Decreases of monocyte chemoattractant protein‐1 and LPS were more significant in patients whose HbA1c decrease was ≥1%, but there were no significant differences in the changes of other cytokines and gut bacteria between patients with HbA1c <7% and ≥7%. Pearson correlation analysis showed that changes of E nterococcus faecalis were negatively correlated with LPS, while multiple linear regression analysis showed a positive correlation of B ifidobacterium longum with acarbose treatment and the high‐density lipoprotein cholesterol concentration. Conclusions: Acarbose treatment can increase the content of gut B ifidobacterium longum in type 2 diabetes mellitus patients and decrease some inflammatory cytokines independently of its antihyperglycemic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063 · cited 1×
“Type 2 diabetes mellitus (DM) is associated with an increased risk of cardiovascular disease (CVD), which is the major cause of disability and death in DM patients.(1) Acarbose, an α-glucosidase inhibitor that specifically reduces the postprandial rise of glucose concentrations by delaying the absorption of glucose, h…”
BackgroundTLR4 links innate immunity and fatty acid-induced insulin resistance
Shi, H., Kokoeva, M. V., Inouye, K., Tzameli, I., Yin, H., & Flier, J. S. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28898 · Cited by 3,690
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.006 · Cited by 1,981
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · cited 1×
“Acarbose, an α-glucosidase inhibitor that specifically reduces the postprandial rise of glucose concentrations by delaying the absorption of glucose, has been demonstrated to be capable of reducing the incidence of acute coronary syndrome in various clinical trials.(2,3) The STOP-NIDDM study(2) demonstrated that patie…”
BackgroundCreely, S. J., McTernan, P. G., Kusminski, C. M., Fisher, F. M., Da Silva, N. F., Khanolkar, M., Evans, M., Harte, A. L., & Kumar, S. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00302.2006 · Cited by 1,043
Inflammatory Markers and Risk of Type 2 Diabetes
Wang, X., Bao, W., Liu, J., OuYang, Y.-Y., Wang, D., Rong, S., Xiao, X., Shan, Z.-L., Zhang, Y., Yao, P., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0702 · Cited by 820
Hanefeld, M. (2004) · European Heart Journal · doi:10.1016/s0195-668x(03)00468-8 · Cited by 641
Cited by
Koutnikova, H., Genser, B., Monteiro-Sepulveda, M., Faurie, J.-M., Rizkalla, S., Schrezenmeir, J., & Clément, K. (2019) · BMJ Open · doi:10.1136/bmjopen-2017-017995 · Cited by 299
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Gut microorganisms as promising targets for the management of type 2 diabetes
Delzenne, N. M., Cani, P. D., Everard, A., Neyrinck, A. M., & Bindels, L. B. (2015) · Diabetologia · doi:10.1007/s00125-015-3712-7 · Cited by 262
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Gut microbiota in the pathogenesis and therapeutic approaches of diabetes
Crudele, L., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104821 · Cited by 251
Starch Digestion by Gut Bacteria: Crowdsourcing for Carbs
Cerqueira, F. M., Photenhauer, A. L., Pollet, R. M., Brown, H. A., & Koropatkin, N. M. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2019.09.004 · Cited by 187
González, N., Diabetes Cancer Connect Consortium, Prieto, I., del Puerto-Nevado, L., Portal-Nuñez, S., Ardura, J. A., Corton, M., Fernández-Fernández, B., Aguilera, O., Gomez-Guerrero, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14472 · Cited by 168
Effects of Antidiabetic Drugs on Gut Microbiota Composition
Montandon, S., & Jornayvaz, F. (2017) · Genes · doi:10.3390/genes8100250 · Cited by 135
“Whereas Escherichia probably plays an important role in the side-effects of metformin [19], Bifidobacterium adolescentis has been shown to negatively correlate to HbA1c.”
BackgroundInfluentialTargeting the human gut microbiome with small-molecule inhibitors
Woo, A. Y. M., Aguilar Ramos, M. A., Narayan, R., Richards-Corke, K. C., Wang, M. L., Sandoval-Espinola, W. J., & Balskus, E. P. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00471-4 · Cited by 42
Wang, X., Xu, T., Liu, R., Wu, G., Gu, L., Zhang, Y., Zhang, F., Fu, H., Ling, Y., Wei, X., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.806331 · Cited by 42
“Acarbose has been confirmed to increase the gut content of Bifidobacteria (21) and was once used to treat PCOS (22).”
BackgroundHu, D., Liu, W., Yu, W., Huang, L., Ji, C., Liu, X., & Lu, Z. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2197076 · Cited by 21
Li, J., Li, J., Shan, Z., Yang, W., Liu, J., Tian, H., Zhou, Z., Ji, Q., Weng, J., Jia, W., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0006 · Cited by 16
“It has been demonstrated that acarbose could regulate the intestinal microbiota composition [17-20].”
BackgroundSelf-citation
Metadata
- Authors
- Su, B., Liu, H., Li, J., Sunli, Y., Liu, B., Liu, D., Zhang, P., & Meng, X.
- Venue
- Journal of Diabetes
- Publisher
- Wiley
- Published
- 2015-01-15
- Volume
- 7
- Issue
- 5
- Pages
- 729-739
- ISSN
- 1753-0393 (ISSN-L)
- 1753-0407
- OpenAlex
- W1928552205
- Cited by
- 137
- References
- 15
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.